T-cell Therapy Market (2026 - 2033)

T-cell Therapy Market Summary

The global T-cell therapy market size was valued at USD 7.1 billion in 2025 and is projected to grow from USD 9.7 billion in 2026 to USD 80.2 billion in 2033, at a CAGR of 35.3% from 2026 to 2033. North America dominated the market, accounting for the largest share of 47.5% in 2025. With the approval of Tecartus, Yescarta, and Kymriah, various entities have shifted their business models from developing small-molecule and protein-based treatments to adoptive therapies.

Modality Insights

By modality, the research-based segment held the largest market share in 2025, driven by the substantial number of T-cell therapy candidates progressing through preclinical and clinical development. Academic medical centers, research institutes, and biotechnology companies continue to invest in novel CAR-T and T-cell receptor (TCR) therapies to expand treatment options across multiple cancer indications. The segment benefits from ongoing translational research activities aimed at improving therapeutic efficacy, safety, and target specificity. Collaborative research initiatives continue to support pipeline advancement. For instance, in April 2025, Moffitt Cancer Center expanded its collaboration with Galapagos NV to strengthen manufacturing and research capabilities for CAR-T therapies in the U.S. Southeast region. The collaboration focuses on advancing decentralized cell therapy manufacturing and developing stem-like early memory T-cell products, supporting ongoing innovation within the research-stage T-cell therapy landscape.

The commercialized products segment is expected to grow significantly over the forecast period, driven by increasing regulatory approvals and broader adoption of approved T-cell therapies across hospitals and specialized cancer centers. The commercialization of CAR-T therapies for hematological malignancies continues to expand as healthcare providers gain greater experience in administering these treatments. Regulatory measures are also supporting wider access. The U.S. Food and Drug Administration removed the REMS requirements for approved BCMA- and CD19-directed CAR-T therapies, reducing administrative requirements for treatment centers and facilitating patient access. Such regulatory developments are expected to support the broader commercial adoption of approved T-cell therapies across established healthcare settings.

Therapy Type Insights

CAR-T therapies held the highest share of over 75.5% in 2025, owing to exponential growth in the number of CAR-T clinical studies and rising engagement by major players in this market. Clinical studies for CAR-T therapy products are being conducted by a significant number of new players and academic institutions for both the same and different indications, strengthening the segment's dominance. The use of CAR-T therapies in the treatment of various cancers has increased due to improvements in their manufacturing. The emergence of new strategies, such as second- and next-generation CAR-T immunotherapies, can overcome challenges like resistance and adverse effects, thereby increasing organic revenue.

T-cell receptor-based therapies are expected to grow at the fastest CAGR during the forecast period, owing to their ability to target intracellular tumor antigens inaccessible to conventional CAR-T therapies. This capability makes TCR therapies particularly attractive for treating solid tumors, where effective cell therapy options remain limited. Growing clinical research activities and advancements in T-cell engineering are further supporting segment expansion. In 2024, the U.S. Food and Drug Administration approved Adaptimmune’s TECELRA (afamitresgene autoleucel), the first TCR-T cell therapy for the treatment of advanced synovial sarcoma. Such developments are strengthening the commercial and clinical prospects of TCR-based therapies in oncology.

Indication Insights

Hematological malignancies accounted for the largest revenue share, at around 46.5% in 2025, driven by the growing adoption of CAR T-cell therapies for the treatment of leukemia, lymphoma, and multiple myeloma. The segment benefits from an expanding portfolio of FDA-approved CD19- and BCMA-targeted therapies that have demonstrated significant clinical efficacy in hematologic cancers.

Continued label expansions are further strengthening the commercial use of these therapies. For instance, in March 2024, Bristol Myers Squibb received U.S. FDA approval for Breyanzi (lisocabtagene maraleucel) as a treatment option for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The approval marked an important milestone for CAR-T therapies, as Breyanzi became the first therapy of its kind authorized for patients with these hematologic malignancies.

Solid tumors are expected to grow significantly during the forecast period, driven by increasing research efforts to expand the application of T-cell therapies beyond hematological malignancies. Advancements in cell engineering, target identification, and combination treatment approaches are enhancing the potential of T-cell therapies for solid-tumor indications. Despite ongoing challenges related to tumor infiltration, cellular persistence, and the immunosuppressive tumor microenvironment, companies and research institutions continue to invest in novel strategies to enhance therapeutic efficacy. The growing number of clinical studies evaluating T-cell therapies across multiple solid tumor indications is expected to support the long-term expansion of this segment.

Regional Insights

The T-cell therapy market in North America accounted for approximately 47.5% of revenue in 2025, supported by a well-established biotechnology ecosystem, a strong clinical research infrastructure, and major cell therapy developers. Growing adoption of approved CAR-T therapies, favorable reimbursement frameworks, and continued regulatory support have strengthened market growth across the United States and Canada.

Manufacturing investments are also expanding regional capabilities. For instance, in February 2026, Johnson & Johnson announced an investment of more than USD 1 billion to build a new cell therapy manufacturing facility in Pennsylvania, U.S. The facility is intended to expand production capacity for advanced therapies targeting cancer and immune disorders, strengthen the region's cell therapy manufacturing infrastructure, and support the commercialization of T-cell therapies.

Asia Pacific T-Cell Therapy Market Trends

The T-cell therapy market in the Asia Pacific region is expected to grow at the fastest CAGR during the forecast period, driven by increasing clinical research activity, supportive government initiatives, and growing investments in cell therapy development. China remains a key growth market and accounts for a substantial share of global CAR-T clinical trials. The country's expanding biotechnology sector, improving regulatory environment, and rising commercialization of domestically developed therapies continue to support market expansion.

Key T-Cell Therapy Company Insights

The market is characterized by intense competition driven by continuous advancements in cell engineering, manufacturing technologies, and product development. Leading companies are focused on expanding their clinical pipelines, strengthening manufacturing capabilities, and pursuing strategic collaborations to enhance their market position.

Established participants such as Novartis AG and Gilead Sciences Inc. (Kite Pharma) continue to maintain a strong presence through their commercial CAR-T therapy portfolios, while emerging companies are investing in next-generation T-cell platforms targeting both hematological malignancies and solid tumors.

Key T-Cell Therapy Companies

The following key companies have been profiled for this study on the T-cell therapy market

• Novartis AG

• Merck KGaA

• Gilead Sciences Inc.

• Bluebird Bio Inc.

• Fate Therapeutics

• Pfizer Inc.

• Amgen

• Bristol Myers Squibb

• Adaptimmune Therapeutics plc

• Autolus Therapeutics plc

Recent Developments

• In November 2025, Kelonia Therapeutics entered into a strategic collaboration with Johnson & Johnson to advance in vivo CAR-T therapies. The collaboration combines Kelonia's targeted gene-delivery technology with Johnson & Johnson's expertise in cell-therapy development to support next-generation treatment approaches.

• In March 2025, Adaptimmune reported continued progress in the commercialization of TECELRA, supported by the expansion of its authorized treatment center network to 20 centers across the U.S. The development strengthened patient access and supported the commercial adoption of the company's TCR-T therapy platform.

• In January 2025, Roche completed the acquisition of Poseida Therapeutics to strengthen its cell therapy pipeline. The acquisition expanded Roche's capabilities in allogeneic CAR-T therapies and genetic medicines for oncology and autoimmune diseases.

T-cell Therapy Market Report Scope

Global T-cell Therapy Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global T-cell therapy market report based on mobility type, therapy type, indication, and region:

• Modality Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Research

  • Commercialized
    

• Therapy Type Outlook (Revenue, USD Million, 2021 - 2033)

  • CAR T-cell Therapy

  • T Cell Receptor (TCR)-based

  • Tumor Infiltrating Lymphocytes (TIL)-based

• Indication Outlook (Revenue, USD Million, 2021 - 2033)

  • Hematologic Malignancies

    • Lymphoma

    • Leukemia

    • Myeloma

  • Solid Tumors

    • Melanoma

    • Brain & Central Nervous System

    • Liver Cancer

    • Others

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

  • Asia Pacific

    • Japan

    • China

  • Rest of the World